4.7 Article

Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke

期刊

CIRCULATION RESEARCH
卷 130, 期 8, 页码 1167-1186

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCRESAHA.121.319994

关键词

COVID-19; depression; humans; microglia; monocytes

资金

  1. DFG (Deutsche Forschungsgemeinschaft) under Germany's Excellence Strategy [EXC-2049-390688087]
  2. BMBF (Bundesministerium fur Bildung und Forschung)
  3. DZNE (Deutsches Zentrum fur Neurodegenerative Erkrankungen)
  4. DZHK (Deutsches Zentrum fur Kardiovaskulare Forschung)
  5. European Union (EU)
  6. Corona Foundation
  7. Foundation Leducq
  8. German Research Foundation [SFB/TRR167, ME 1562/4-1]
  9. Einstein Foundation [A-2017-406]
  10. Foundation Leducq [19CVD01, 21CVD04]
  11. American Heart Association (AHA)/Allen Brain Health Award [19PABHI34580007]
  12. Spanish Ministry of Science and Innovation (MCIN) [PID2019-106581RB-I00]
  13. Instituto de Salud Carlos III
  14. MCIN
  15. Pro CNIC Foundation

向作者/读者索取更多资源

Inflammation and immune mechanisms play crucial roles in the development, complications, and outcomes of ischemic stroke. Anti-inflammatory drugs show promise in preventing stroke, and the COVID-19 pandemic has highlighted the association between infections and cerebrovascular events. Different immune cells and molecules contribute to cerebral damage and chronic inflammation after stroke. Chronic systemic inflammation and comorbid infections can affect recovery after stroke and increase the risk of recurrence. Immune mechanisms may also play a role in specific complications of stroke.
Inflammation and immune mechanisms are crucially involved in the pathophysiology of the development, acute damage cascades, and chronic course after ischemic stroke. Atherosclerosis is an inflammatory disease, and, in addition to classical risk factors, maladaptive immune mechanisms lead to an increased risk of stroke. Accordingly, individuals with signs of inflammation or corresponding biomarkers have an increased risk of stroke. Anti-inflammatory drugs, such as IL (interleukin)-1 beta blockers, methotrexate, or colchicine, represent attractive treatment strategies to prevent vascular events and stroke. Lately, the COVID-19 pandemic shows a clear association between SARS-CoV2 infections and increased risk of cerebrovascular events. Furthermore, mechanisms of both innate and adaptive immune systems influence cerebral damage cascades after ischemic stroke. Neutrophils, monocytes, and microglia, as well as T and B lymphocytes each play complex interdependent roles that synergize to remove dead tissue but also can cause bystander injury to intact brain cells and generate maladaptive chronic inflammation. Chronic systemic inflammation and comorbid infections may unfavorably influence both outcome after stroke and recurrence risk for further stroke. In addition, stroke triggers specific immune depression, which in turn can promote infections. Recent research is now increasingly addressing the question of the extent to which immune mechanisms may influence long-term outcome after stroke and, in particular, cause specific complications such as poststroke dementia or even poststroke depression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据